Illumina (NASDAQ:ILMN) announced today that the company has filed an additional patent infringement suit against Complete Genomics, Inc. Illumina is seeking all available remedies, including injunctive relief.
The new suit, filed in the U.S. District Court for the Southern District of California, is based on Complete Genomics' infringement of U.S. Patent No. 8,192,930, entitled "Method for Sequencing a Polynucleotide Template." The suit targets Complete Genomics' Combinatorial Probe-Anchor Ligation (cPal) read technology.
Illumina previously sued Complete Genomics for infringement of U.S. Patent No. 6,306,597, in the U.S. District Court for the Northern District of California. On February 8, 2012, the Court in that case issued a Claim Construction Order providing the Court's interpretation of the disputed patent terms which affirmed the breadth of the patent and supports Illumina's position that Complete Genomics infringes that patent.
Illumina is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. Illumina owns or has exclusive licenses to more than 250 patents granted in the U.S. and many additional patents granted worldwide.
Illumina donates more than 95,000 human genetic variants to ClinVar database